GSK's involvement in the extended Series C financing and the strategic collaboration to develop a promising tuberculosis treatment could be viewed positively by investors, potentially leading to a positive short-term impact on GSK's stock price. The investment in healthcare innovation, especially in a high-impact area like tuberculosis treatment, aligns with GSK's strategic interests and could enhance its market position and investor perception.